At 23x forward earnings, with every segment's operating metrics improving, the market is underpricing RTX's near-term operational momentum: aircraft on ground falling, Collins cost actions landing, Raytheon converting a 2.4x book-to-bill.
Read Article ›The market has marked down a franchise for a threat it cannot yet feel, and at 37 times forward earnings Howmet is worth owning — not for a re-rating to $328, but because the business is compounding faster than the multiple needs to expand.
Read Article ›At 16 times forward earnings, this price embeds no margin expansion, no buyback, and a backlog that converts on the market's timetable rather than the contract's.
Read Article ›The market has taken the world’s most-owned stock and, inside two months, compressed it to roughly 22–24x consensus NTM / FY27 earnings — not clearly below the S&P 500, but strikingly close to a market multiple for a company whose revenue just grew 85% year over year — on a be...
Read Article ›The familiar standoff—elite CF monopoly versus a full multiple and a maturing core—resolves in the buyers' favor once you weight the catalysts by how knowable they are. CF is converting toward ALYFTREK on a long exclusivity runway and funding everything else; that is the demon...
Read Article ›Summary Vertex enters a catalyst rich mid 2026 trading at roughly 22 times forward earnings—a discount that undervalues the company& 39;s evolving profile—despite a fortress cystic fibrosis franchise, three newer products gaining traction, and a renal pipeline asset that just ...
Read Article ›